Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis

Sicheng Zhou†, Yujuan Jiang†, Wei Pei, Jianwei Liang* and Zhixiang Zhou*

Abstract

Aim: It is still controversial whether the addition of lateral pelvic lymph node (LPN) dissection (LPND) to total mesorectal excision (TME) can provide a survival benefit after neoadjuvant chemoradiotherapy (nCRT) in rectal cancer patients with pathological lateral lymph node metastasis (LPNM).

Methods: Patients with clinically suspected LPNM who underwent nCRT followed by TME + LPND were systematically reviewed and divided into the positive LPN group (n = 15) and the negative LPN group (n = 58). Baseline characteristics, clinicopathological data and survival outcomes were collected and analysed.

Results: Of the 73 patients undergoing TME + LPND after nCRT, the pathological LPNM rate was 20.5% (15/73). Multivariate analysis showed that a post-nCRT LPN short diameter ≥ 7 mm (OR 49.65; 95% CI 3.98–619.1; P = 0.002) and lymphatic invasion (OR 9.23; 95% CI 1.28–66.35; P = 0.027) were independent risk factors for pathological LPNM. The overall recurrence rate of patients with LPNM was significantly higher than that of patients without LPNM (60.0% vs 27.6%, P = 0.018). Multivariate regression analysis identified that LPNM was an independent risk factor not only for overall survival (OS) (HR 3.82; 95% CI 1.19–12.25; P = 0.024) but also for disease-free survival (DFS) (HR 2.33; 95% CI 1.02–5.14; P = 0.044). Moreover, N1–N2 stage was another independent risk factor for OS (HR 7.41; 95% CI 1.63–33.75; P = 0.010).

Conclusions: Post-nCRT LPN short diameter ≥ 7 mm and lymphatic invasion were risk factors for pathological LPNM after nCRT. Furthermore, patients with pathological LPNM still show an elevated overall recurrence rate and poor prognosis after TME + LPND. Strict patient selection and intensive perioperative chemotherapy are crucial factors to ensure the efficacy of LPND.

Keywords: Lateral pelvic lymph node dissection, Rectal cancer, Recurrence, Prognosis

Statement

For patients with pathological LPNM, whether the employment of nCRT can reduce the local recurrence rate and improve survival is still not clear. The aim of this study was to identify risk factors for LPNM and investigate the oncological outcomes and prognostic values.
Introduction
The lateral pelvic lymph node (LPN) is one of the common lymphatic metastasis areas of middle-low rectal cancer, and it has been reported that approximately 10–20% of rectal cancer patients with stage II-III disease develop LPN metastasis (LPNM) outside the field of total mesorectal excision (TME) [1, 2]. Most hospitals in Japan adopt a more active treatment attitude, and a prospective multicentre RCT (JCOG0212) conducted in Japan demonstrated that TME with ‘prophylactic’ LPN dissection (LPND) significantly decreased local recurrence rates compared with TME alone for patients who do not have LPN enlargement before surgery (7.4% vs 12.6%) [3]. In addition, the guidelines 2019 of the Japanese Society for Cancer of the Colon and Rectum recommend that TME + LPND should be performed if a preoperative or intraoperative diagnosis reveals the presence of LPNM [4]. However, recent literature has shown that, even with TME + LPND, patients with LPNM still show an increased risk of local recurrence and distant metastasis, resulting in a poor prognosis [5, 6]. In contrast, neoadjuvant chemoradiotherapy (nCRT) followed by TME was mostly employed for locally advanced rectal cancer, and several relevant randomized control studies revealed that, compared with TME alone, nCRT followed by TME could reduce the local recurrence rate by approximately 10% in clinical II or III rectal cancer patients [7, 8]. However, most of the patients in the above study had no LPNM, and the current opinion suggests that nCRT + TME without LPND is not sufficient for patients with enlarged LPN, with a lateral pelvic recurrence rate of 19.5% in patients with a LPN diameter greater than 7 mm [9–12].

In recent years, the literature has shown that TME plus selective LPND, according to indications after nCRT, can bring maximum therapeutic benefits to patients with suspicion of LPNM [13–16]. However, relevant studies on the prognostic factors of TME + LPND after nCRT in patients with suspicion of LPNM are few [17, 18]. In addition, for patients with pathological LPNM, whether the employment of nCRT can reduce the local recurrence rate and improve survival is still not clear. In the present study, patients with suspicion of LPNM based on preoperative images were selected, and all patients received TME + LPND after receiving nCRT. The aim of this study was to identify risk factors for LPNM and investigate the oncological outcomes and prognostic values for rectal cancer patients treated with TME + LPND following nCRT.

Materials and methods
Patients
A total of 83 low-middle rectal cancer patients with suspicion of LPNM who underwent TME + LPND after nCRT at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between January 2015 and January 2021 were retrospectively collected and analysed. The inclusion criteria were as follows: (1) histologically confirmed adenocarcinoma; (2) lower tumour margin below the peritoneal reflection; and (3) suspicion of LPNM based on magnetic resonance imaging (MRI) evaluation. Patients with a previous history of other malignant tumours or achieved clinical complete response after nCRT and opted for watch and wait were excluded from this study. Finally, 73 patients met the above criteria and were included in the study. The ethics committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College approved this study (NCC 2017-YZ-026, 17 October 2017). The study was conducted in accordance with the ethical standards of the World Medical Association Declaration of Helsinki and all methods were carried out in accordance with relevant guidelines and regulations. Prior written informed consent was obtained from all study participants.

Diagnosis and treatment strategy
Lateral lymph node metastasis was evaluated by preoperative magnetic resonance imaging (MRI) in all patients, and the diagnostic criteria for LPNM were as follows: (1) short diameter of LPN > 8 mm; (2) inhomogeneous or intense enhancement; and (3) irregular shape with rough edges. Those patients meeting one or more of the above criteria can be diagnosed as having LPNM. Clinical stage and LPN status before and after treatment were evaluated according to imaging radiologists who specialized in colorectal cancer and the LPN short diameter was measured with electronic calipers on pelvic MRI. In addition, the two imaging radiologists who performed the preoperative evaluation were single-blind to patients information. The American Joint Committee on Cancer (AJCC, ninth edition) staging system was used for tumour staging. Lymph nodes in the area lying along the inferior mesenteric vessels, except LPN, were considered regional lymph nodes. All patients received nCRT, which consisted of a total radiation dose of 50 Gy (50 Gy/25 f/2 Gy) and oral capecitabine at a dose of 825 mg/m² twice daily. TME + LPND was performed 6–8 weeks after completion of the last CRT. In present study, we decided to set 7 mm as the cut-off for post-nCRT LPN short diameter
according to our previous research results and previous literature reports [14, 16].

Surgical procedure
The LPND procedure (open or laparoscopic) was standardized, and unilateral or bilateral lymph node dissection was performed based on the location of the observed swollen LPN. The extent of LPLN includes internal iliac vessels (Region 263), external iliac vessels (Region 293), common iliac vessels (Region 273), and obturator lymph nodes (Region 283) that are distributed in the lateral pelvic area outside the pelvic plexus and hypogastric nerves [19].

Follow-up
Follow-up was scheduled through telephone or outpatient visits every 3–6 months for the first 3 years and every 6 months thereafter until death due to recurrence or metastasis of rectal cancer or 1 February 2021, whichever came first. Tumour markers, computed tomography (CT), and pelvic MRI were examined during each follow-up. Local recurrence is defined as the recurrence of tumors with the same pathologic properties as the primary cancer at the site or surgical field after rectal cancer surgery, including anastomosis, mesentery, perineum, presacral tissue, genitourinary, pelvic lateral wall, etc.

Statistical analysis
Analyses were performed using SPSS for Windows version 20.0 (SPSS, Chicago, Illinois, USA). Categorical variables and continuous variables are expressed as frequencies (percentages) and medians (ranges), respectively. Categorical variables were compared using the χ² test or Fisher's exact test. The statistically significant variables were included in multivariate analysis, and the results showed that post-nCRT LPN short diameter ≥ 7 mm (OR 49.65; 95% CI 3.98–619.1; P = 0.002) and lymphatic invasion (OR 9.23; 95% CI 1.28–66.35; P = 0.027) were identified as independent risk factors for pathological LPNM (Table 3).

Postoperative Recurrence and Survival Analysis
The median follow-up period of the whole group was 28.0 (range 2–66) months. In total, 15 (20.5%) patients died, and 25 (34.2%) patients developed local recurrence or distant metastasis during follow-up. The postoperative overall recurrence rate of patients with LPNM was higher than that of patients without LPNM (60.0% vs 27.6%, P = 0.018). Although the local recurrence rate (26.7% vs 6.9%, P = 0.085) and distant metastasis rate (40.0% vs 22.4%, P = 0.292) were higher in patients with LPNM, the difference was not statistically significant (Table 4).

The Kaplan curves showed that the OS (P = 0.006) and DFS (P = 0.018) of patients with LPNM were significantly lower than those without LPNM. The Kaplan curves showed that OS and DFS were significantly lower in patients with LPNM.
worse than those of patients without LPNM (Figs. 1 and 2). The 1-, 2- and 3-year OS rates were 85.7% vs. 94.3%, 67.5% vs. 86.7% and 46.3% vs. 83.7% in patients with or without LPNM, respectively. The 1-, 2- and 3-year DFS rates were 42.9% vs. 79.9%, 34.3% vs. 75.9% and 34.3% vs. 67.3% in patients with or without LPNM, respectively (Table 5).

Univariate and multivariate regression analyses were conducted to identify prognostic factors for OS and DFS of patients who underwent TME + LPND. Univariate analysis showed that adverse pathological types, N1–N2 stage, and LPNM were associated with poor OS ($P<0.05$). In addition, DFS was significantly affected by the pre-nCRT CEA level, N1–N2 stage and LPNM ($P<0.05$). Multivariate regression analysis identified that LPNM was an independent risk factor not only for OS (HR 3.82; 95% CI 1.19–12.25; $P=0.024$) but also for DFS (HR 2.33; 95% CI 1.02–5.14; $P=0.044$). Moreover, N1–N2 stage was another independent risk factor for OS (HR 7.41; 95% CI 1.63–33.75; $P=0.010$) (Table 6).

Discussion

Previous studies from Eastern and Western countries have reported that, for patients with preoperative lateral lymph node enlargement, nCRT without LPND results in a high rate of lateral pelvic recurrence after surgery [20–22]. Therefore, we conducted a retrospective study to explore the surgical indications for LPND after nCRT for patients with suspected LPNM before surgery and to investigate the oncological outcomes and prognostic values for rectal cancer patients treated with TME + LPND following nCRT. Our results preliminarily found indications of LPND after nCRT in patients with low-middle rectal cancer, and that the current treatment strategy for LPNM is inadequate. Therefore, the purpose of this study was to explore the causes of poor prognosis in patients with LPNM and to explore ways to potentially improve treatment strategies.

In previous studies, the incidence of LPNM for patients with stage II–III rectal cancer was demonstrated to be 10–20% [1, 2]. All the patients included in the present study were suspected of having LPNM by preoperative MRI evaluation, and the rate of pathological LPNM was only 20.5%, which is related to the relatively loose imaging diagnostic criteria of LPNM. The present study showed that pathological LPNM was significantly affected by post-nCRT size and lymphatic invasion. The selection of the optimal cut-off value of post-nCRT LPN size remains controversial, with the most common cut-off values currently being 5 mm [1, 23, 24] and 7 mm [14, 16]. Chen et al. reported that persistent LPN size $\geq 7$ mm on post-nCRT MRI was significantly associated with LPNM after nCRT (OR 7.539, 95% CI 1.49–38.21; $P=0.015$) [16]. Furthermore, Inoue et al., however, thought that 7 mm could be a more appropriate cut-off [14]. In our study, we set 7 mm as the cut-off for post-nCRT LPN size. As a result, 93.3% (14/15) and 24.1% (14/58) of patients with LPN short diameter $\geq 7$ mm were found in the positive and negative LPN groups, respectively. Multivariate logistic regression analysis demonstrated that a post-nCRT LPN short diameter $\geq 7$ mm (OR 49.65; 95% CI 3.98–619.1; $P=0.002$) and lymphatic invasion (OR 9.23; 95%
CI 1.28–66.35; \( P = 0.027 \) were independent risk factors for pathological LPNM, and these results were consistent with the above mentioned results. Rectal lymphatic circumfluence can be divided into three directions: upward, lateral and downward. The lateral rectal ligament is rich in blood vessels and lymph nodes, which is

| Variables                              | Positive LPN (n = 15) | Negative LPN (n = 58) | P    |
|----------------------------------------|-----------------------|-----------------------|------|
| Gender                                 |                       |                       | 0.493|
| Male                                   | 10 (66.7)             | 33 (56.9)             |      |
| Female                                 | 5 (33.3)              | 25 (43.1)             |      |
| Age (years)                            |                       |                       | 0.786|
| \( \leq 60 \)                          | 9 (60.0)              | 37 (63.8)             |      |
| \( > 60 \)                             | 6 (40.0)              | 21 (36.2)             |      |
| Distance from the AV (cm)              |                       |                       | 0.923|
| \( < 5 \)                              | 9 (60.0)              | 34 (58.6)             |      |
| \( 5–10 \)                             | 6 (40.0)              | 24 (41.4)             |      |
| Post-nCRT LPN short diameter (mm)      |                       |                       | <0.001|
| \( < 7 \)                              | 1 (6.7)               | 44 (75.9)             |      |
| \( \geq 7 \)                           | 14 (93.3)             | 14 (24.1)             |      |
| LPN intensity                          |                       |                       | 0.141|
| Normal                                 | 7 (46.7)              | 39 (67.2)             |      |
| Inhomogeneous or intense enhancement   | 8 (53.3)              | 19 (32.8)             |      |
| LPN shape                              |                       |                       | 0.046|
| Normal                                 | 5 (33.3)              | 36 (62.1)             |      |
| Irregular shape or rough edges         | 10 (66.7)             | 22 (37.9)             |      |
| Pre-nCRT CEA level (ng/ml)             |                       |                       | 0.979|
| \( < 5 \)                              | 12 (80.0)             | 49 (84.5)             |      |
| \( \geq 5 \)                           | 3 (20.0)              | 9 (15.5)              |      |
| ypT stage                              |                       |                       | 0.025|
| T1–2                                   | 2 (13.3)              | 26 (44.8)             |      |
| T3–4                                   | 13 (86.7)             | 32 (55.2)             |      |
| ypN stage                              |                       |                       | 0.080|
| N0                                     | 5 (33.3)              | 34 (58.6)             |      |
| N1–2                                   | 10 (66.7)             | 24 (41.4)             |      |
| Mesorectal LN metastasis               | 3.4 ±6.2              | 1.4 ±2.5              | 0.151|
| Histology                              |                       |                       | 0.027|
| Moderate                               | 9 (60.0)              | 50 (86.2)             |      |
| Poor/Mucinous/signet adenocarcinoma    | 6 (40.0)              | 8 (13.8)              |      |
| Lymphatic invasion                     | 8 (53.3)              | 9 (15.5)              | 0.006|
| Perineural invasion                    | 7 (46.7)              | 16 (27.6)             | 0.269|
| Vascular invasion                      | 5 (33.3)              | 11 (19.0)             | 0.396|
| Types of operation (%)                 |                       |                       | 0.771|
| Low anterior resection                 | 6 (40.0)              | 20 (34.5)             |      |
| Abdominoperineal resection             | 8 (53.3)              | 36 (62.1)             |      |
| Hartmann procedure                     | 1 (6.7)               | 2 (3.4)               |      |
| LPND type (%)                          |                       |                       | 1.000|
| Unilateral dissection                  | 11 (73.3)             | 44 (75.9)             |      |
| Bilateral dissection                   | 4 (26.7)              | 14 (24.1)             |      |
| Adjuvant chemotherapy                  | 13 (86.6)             | 41 (70.7)             | 0.296|

SD standard deviation, BMI body mass index, AV anal verge, LPN lateral pelvic lymph node, LPNM lateral pelvic lymph node metastasis, LPND lateral pelvic lymph node dissection.
considered as a lymphatic pathway between low rectum and lateral region. Therefore, the occurrence of LPNM should be highly vigilant in patients with lymphatic invasion, and adjuvant therapy should be strengthened during perioperative period while complete resection of the lateral rectal ligament.

A meta-analysis of 18 studies involving 6133 patients suggested that additional LPND results in greater postoperative morbidity, urinary dysfunction, and sexual dysfunction, without improving recurrence and long-term survival [25]. Moreover, it has been reported that patients with pathological LPNM, even after TME + LPND, still have a higher local recurrence rate and a worse prognosis than patients without pathological LPNM [5, 6, 26–28]. However, the role of nCRT in LPNM has become clearer in recent years, and this study investigated the oncology outcomes of TME + LPND after nCRT for patients with LPNM. Our study demonstrated that patients with pathological LPNM who received TME + LPND after nCRT still showed a higher overall recurrence rate after surgery (60.0% vs 27.6, \( P = 0.018 \)). Similarly, a retrospective study involving 899 patients at a high-volume cancer centre in Japan conducted by Wang et al. revealed that, even with LPND, patients with pathological LPNM still showed an elevated risk of local recurrence (30.0% vs 10.0, \( P = 0.025 \)) [5]. Meanwhile, the present study revealed that the 3-year OS (46.3% vs 83.7%, \( P = 0.006 \)) and DFS (34.3% vs 67.3%, \( P = 0.018 \)) of patients with LPNM were significantly worse than those without LPNM, and the multivariate regression analysis identified that LPNM was an independent risk factor not only for OS (HR 3.82; 95% CI 1.19–12.25; \( P = 0.024 \)) but also for DFS (HR 2.33; 95% CI 1.02–5.14; \( P = 0.044 \)) through multivariate regression analysis. A retrospective study involving 149 rectal patients conducted by Sato et al. showed that the 5-year OS rate was significantly worse in patients with LPNM (36.2% vs 69.8%, \( P = 0.0004 \)), and multivariate Cox regression analysis for factors affecting the prognosis showed that LLN metastases had an independent predictive value in determining prognosis (HR 2.41; 95% CI 1.37–4.26; \( P = 0.002 \)) [28], which is basically consistent with our results. Considering the greater postoperative morbidity, urinary dysfunction, and sexual dysfunction associated with LPND, we suggest that it is necessary to explore which

### Table 3 Multivariate analysis of LPNM for 73 patients after nCRT

| Variables                                      | OR   | 95% CI       | \( P \) |
|------------------------------------------------|------|--------------|--------|
| Poor/Mucinous/signet adenocarcinoma            | 2.83 | 0.41–19.66   | 0.294  |
| Post-nCRT LPN short diameter \( \geq 7 \) mm   | 49.65| 3.98–619.1   | 0.002  |
| ypT3–4                                         | 2.93 | 0.36–23.73   | 0.314  |
| Lymphatic invasion                             | 9.23 | 1.28–66.35   | 0.027  |
| Irregular LPN shape or rough edges             | 2.73 | 0.49–15.36   | 0.254  |

AV: anal verge, LPN: lateral pelvic lymph node, LPNM: lateral pelvic lymph node metastasis, LPND: lateral pelvic lymph node dissection

### Table 4 Postoperative recurrence of 73 patients with or without pathological LPNM

|                        | Positive LPN (n = 15) | Negative LPN (n = 58) | \( P \) |
|------------------------|-----------------------|-----------------------|--------|
| Overall recurrence (%) | 9 (60.0)              | 16 (27.6)             | 0.018  |
| Local recurrence       | 4 (26.7)              | 4 (6.9)               | 0.085  |
| Distant metastasis     | 6 (40.0)              | 13 (22.4)             | 0.292  |
| Liver metastasis       | 4 (26.7)              | 7 (12.1)              |        |
| Lung metastasis        | 1 (6.7)               | 6 (10.3)              |        |
| Bone metastasis        | 1 (6.7)               | 2 (3.4)               |        |
| Peritoneal metastasis  | 1 (6.7)               | 0 (0)                 |        |
| Others                 | 0 (0)                 | 1 (1.7)               |        |

LPN: lateral pelvic lymph node, LPNM: lateral pelvic lymph node metastasis, node dissection

### Fig. 1 Overall survival curve

**Overall survival of 73 patients with or without pathological LPNM**

**Fig. 2 Disease-free survival of 73 patients with or without pathological LPNM**

**Table 4 Postoperative recurrence of 73 patients with or without pathological LPNM**

|                        | Positive LPN (n = 15) | Negative LPN (n = 58) | \( P \) |
|------------------------|-----------------------|-----------------------|--------|
| Overall recurrence (%) | 9 (60.0)              | 16 (27.6)             | 0.018  |
| Local recurrence       | 4 (26.7)              | 4 (6.9)               | 0.085  |
| Distant metastasis     | 6 (40.0)              | 13 (22.4)             | 0.292  |
| Liver metastasis       | 4 (26.7)              | 7 (12.1)              |        |
| Lung metastasis        | 1 (6.7)               | 6 (10.3)              |        |
| Bone metastasis        | 1 (6.7)               | 2 (3.4)               |        |
| Peritoneal metastasis  | 1 (6.7)               | 0 (0)                 |        |
| Others                 | 0 (0)                 | 1 (1.7)               |        |

LPN: lateral pelvic lymph node, LPNM: lateral pelvic lymph node metastasis, node dissection

**Sexual dysfunction, without improving recurrence and long-term survival [25].**
types of patients with pathological LPNM can benefit from TME + LPND after nCRT.

Our study found that even if LPND was performed after nCRT, the prognosis of patients with LPNM was often poor. Moreover, it should be noted that the results of our study showed that 1-year DFS in patients with LPNM was only 42.9%, lower than previous literature reports [29]. It may be because at the time of initial diagnosis, micro-metastases of the liver and lungs could not be detected or identifiable. A retrospective study conducted by Hiyoshi et al. also revealed that the prognosis of rectal cancer patients with LPNM is poor, not only in the overall rectal cancer patient population but also in patients with stage IV disease [26]. Therefore, for patients with clinical LPNM, the adequate preoperative examination should be fully evaluated for distant metastasis, and postoperative adjuvant systemic chemotherapy should be strengthened to eliminate micro-metastasis. In addition, several literature demonstrated that LPND appears to confer survival benefits to certain patients with single LPN involvement in the obturator region or internal iliac vessel region [30, 31]. Therefore, appropriate patient selection are also important factors to ensure the efficacy of LPND.

This study was associated with several limitations, including the retrospective nature and small sample size of only 73 patients included. Second, the study period was from 2015 to 2021, and the adjuvant chemotherapy regimens adopted by the included patients were inconsistent, which may cause some interference

| Table 5 | Overall survival and disease-free survival of 73 patients with or without pathological LPNM |
|---------|---------------------------------|
| N       | Overall survival                | Disease-free survival                      |
|         | 1-year | 2-year | 3-year | 1-year | 2-year | 3-year |
| LPN status |       |        |        |        |        |        |
| Positive LPN | 15  | 85.7%  | 67.5%  | 46.3%  | 42.9%  | 34.3%  | 34.3%  |
| Negative LPN | 58  | 94.3%  | 86.7%  | 83.7%  | 79.9%  | 75.9%  | 67.3%  |

LPN lateral pelvic lymph node, LPNM lateral pelvic lymph node metastasis, node dissection

| Table 6 | Univariate and multivariate analyses for overall survival and disease-free survival of the 73 rectal patients with clinical LPNM who underwent TME + LPND |
|---------|-------------------------------------------------|
| Variables | Overall survival                               | Disease-free survival               |
|          | Univariate analysis                            | Multivariate analysis              |
|          | Univariate analysis                            | Multivariate analysis              |
|          | HR(95%CI) | P      | HR(95%CI) | P      | HR(95%CI) | P      | HR(95%CI) | P      |
| Gender: male/female | 1.01 (0.36–2.83) | 0.993 | 1.19 (0.54–2.63) | 0.660 |
| Age | 1.03 (0.98–1.08) | 0.314 | 1.00 (0.97–1.04) | 0.953 |
| BMI (Kg/m²) | 1.02 (0.86–1.21) | 0.801 | 0.95 (0.83–1.08) | 0.404 |
| Pre-nCRT CEA level | 1.01 (0.99–1.03) | 0.495 | 1.01 (1.00–1.03) | 0.026 | 1.01 (0.97–1.03) | 0.262 |
| Pre-nCRT CA19-9 level | 1.01 (0.99–1.01) | 0.093 | 1.00 (0.99–1.01) | 0.158 |
| Post-nCRT CEA level | 1.09 (0.95–1.26) | 0.220 | 1.04 (0.95–1.13) | 0.399 |
| Post-nCRT CA19-9 level | 1.01 (0.99–1.01) | 0.135 | 1.01 (0.99–1.01) | 0.183 |
| Histology | 3.50 (1.24–9.89) | 0.018 | 2.21 (0.75–6.48) | 0.150 |
| Distance from AV | 1.16 (0.91–1.50) | 0.238 | 1.01 (0.81–1.23) | 0.939 |
| T stage: T3–4/T1–2 | 3.41 (0.70–8.00) | 0.109 | 2.22 (0.89–5.52) | 0.087 |
| N stage: N1–2/N0 | 8.00 (1.80–35.54) | 0.006 | 7.41 (1.63–33.75) | 0.010 | 2.41 (1.05–9.32) | 0.044 | 2.04 (0.93–5.10) | 0.087 |
| LPN metastasis | 4.42 (1.54–12.74) | 0.006 | 3.82 (1.19–12.25) | 0.024 | 2.67 (1.18–6.02) | 0.018 | 2.33 (1.02–5.14) | 0.044 |
| Mesorectal LN harvested | 1.02 (0.98–1.07) | 0.299 | 1.02 (0.98–1.01) | 0.388 |
| LPN harvested | 1.01 (0.94–1.09) | 0.742 | 1.01 (0.96–1.06) | 0.730 |
| Operative time | 1.00 (0.99–1.01) | 0.980 | 1.00 (0.99–1.01) | 0.635 |
| Estimated bleeding | 1.00 (0.99–1.01) | 0.682 | 1.00 (1.00–1.01) | 0.089 |
| Postoperative complications | 0.73 (0.20–2.67) | 0.633 | 0.84 (0.34–2.10) | 0.714 |

BMI body mass index, AV anal verge, LPN lateral pelvic lymph node, LN lymph nodes, LPNM lateral pelvic lymph node metastasis, LPND lateral pelvic lymph node dissection, TME total mesorectal excision
with the prognosis. Secondly, in this study, the DFS of patients with LPNM was only 35.7% in 1 year after surgery, which may be related to inadequate preoperative diagnosis and inadequate treatment strategy. Therefore, the present study does not deny the efficacy of LPND after nCRT; only emphasizes that for patients with LPNM, adequate preoperative evaluation should be carried out, strictly in accordance with LPND indications, to avoid execution in stage IV patients. Moreover, this study only verified the oncology outcomes of LPND for patients with clinically suspected LPNM. It is impossible to compare the local control effect of prophylactic LPND in stage II–III patients with middle-low rectal cancer due to the nonroutine practice of prophylactic LPND in our institution. Finally, the number of patients with pathological LPNM in our analysis was too small to perform an appropriate multivariate analysis to identify which types of patients with LPNM may achieve a survival benefit from LPND. Therefore, randomized controlled studies with larger numbers of patients are needed to further verify our findings.

**Conclusion**

In conclusion, post-nCRT LPN short diameter ≥ 7 mm and lymphatic invasion were risk factors for pathological LPNM after nCRT. Furthermore, patients with pathological LPNM still show an elevated overall recurrence rate and poor prognosis after TME + LPND. Strict patient selection and intensive perioperative chemotherapy are crucial factors to ensure the efficacy of LPND.

**Abbreviations**

TME: Total mesorectal excision; LPND: Lateral pelvic lymph node dissection; nCRT: Neoadjuvant chemoradiotherapy; LPNM: Lateral lymph node metastasis; DFS: Disease-free survival; OS: Overall survival; MRI: Magnetic resonance imaging; AJCC: American Joint Committee on Cancer.

**Acknowledgements**

None.

**Authors’ contributions**

Conception and design were performed by JWL and ZXZ. Material preparation, data collection and analysis were performed by SCZ, YJJ and WP. The first draft of the manuscript was written by SCZ and all authors commented on previous versions of the manuscript. All authors have read and approved the manuscript.

**Funding**

This work was supported by the Beijing Hope Run Special Fund of Cancer Foundation of China (Grant No. LC2017A19). The funders had no role in the design of the study, data collection, analysis, and manuscript writing.

**Availability of data and materials**

The data that support the findings of this study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions.

**Declarations**

**Ethics approval and consent to participate**

The ethics committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College approved this study (NCC 2017-YZ-026, 17 October 2017). The study was conducted to the ethical standards of the World Medical Association Declaration of Helsinki and all methods were carried out in accordance with relevant guidelines and regulations. Prior written informed consent was obtained from all study participants.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 30 September 2021 Accepted: 17 December 2021**

**Published online: 28 December 2021**

**References**

1. Wang P, Zhou S, Zhou H, et al. Evaluating predictive factors for determining the presence of lateral pelvic node metastasis in rectal cancer patients following neoadjuvant chemoradiotherapy. Colorectal Dis. 2019;21(7):791–6.
2. Kanemitsu Y, Komori K, Shida D, et al. Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: a comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. Surgery. 2017;162:303–14.
3. Fujita S, Mizusawa J, Kanemitsu Y, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage I/II/III lower rectal cancer (JCOCG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg. 2017;266:201–7.
4. Hashiguchi Y, Muro K, Saito Y, Japanese Society for Cancer of the Colon and Rectum, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
5. Wang L, Hirano Y, Heng G, et al. The significance of lateral lymph node metastasis in low rectal cancer: a propensity score matching study. J Gastrointest Surg. 2020;25(7):1866–74.
6. Numata M, Tamagawa H, Kazame K, et al. Lateral lymph node dissection for mid-to-low rectal cancer: is it safe and effective in a practice-based cohort? BMC Surg. 2021;21(15):51.
7. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.
8. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.
9. Schaap DP, Ogura A, Nederend J, et al. Prognostic implications of MRI-detected lateral nodal disease and extramural vascular invasion in rectal cancer. Br J Surg. 2018;105:1844–52.
10. Perez RO, Sano Julio GP, Vaillat BB, et al. Lateral node dissection in rectal cancer in the era of minimally invasive surgery: a step-by-step description for the surgeon unacquainted with this complex procedure with the use of the laparoscopic approach. Dis Colon Rectum. 2018;61:1237–40.
11. Malakorn S, Ouchi A, Sammour T, et al. Robotic lateral pelvic lymph node dissection after neoadjuvant chemoradiation: view from the West. Dis Colon Rectum. 2018;61:1119–20.
12. Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol. 2019;37:33–43.
13. Akiyoshi T, Matsueda K, Hiratsuka M, et al. Indications for lateral pelvic lymph node dissection based on magnetic resonance imaging before and after preoperative chemoradiotherapy in patients with advanced low rectal cancer. Ann Surg Oncol. 2013;20(Suppl 3):S614–20.
14. Inoue Y, Saigusa S, Hiro J, et al. Clinical significance of enlarged lateral pelvic lymph nodes before and after preoperative chemoradiotherapy for rectal cancer. Mol Clin Oncol. 2016;4:994–1002.

15. McCawley N, Clancy C, O’Neill BD, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Dis Colon Rectum. 2016;59:1200–8.

16. Chen JN, Liu Z, Wang ZJ, et al. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer. World J Gastroenterol. 2020;26:2877–88.

17. Tomono A, Yamashita K, Kanemitsu K, et al. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Int J Clin Oncol. 2016;21(2):344–9.

18. Ogura A, Akiyoshi T, Nagasaki T, et al. Feasibility of laparoscopic total mesorectal excision with extended lateral pelvic lymph node dissection for advanced lower rectal cancer after preoperative chemoradiotherapy. World J Surg. 2017;41(3):868–75.

19. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum: Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.

20. Kim TG, Park W, Choi DH, et al. Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients. Int J Colorectal Dis. 2014;29:193–200.

21. Kim MJ, Kim TH, Kim DY, et al. Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer? J Surg Oncol. 2015;111:459–64.

22. Kusters M, Slater A, Muirhead R, et al. What to do with lateral nodal disease in low locally advanced rectal cancer? A call for further reflection and research. Dis Colon Rectum. 2017;60:577–85.

23. Oh HK, Kang SB, Lee SM, et al. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study. Ann Surg Oncol. 2014;21:2280–7.

24. Yamaoka Y, Kinugasa Y, Shiomi A, et al. Preoperative chemoradiotherapy changes the size criterion for predicting lateral lymph node metastasis in lower rectal cancer. Int J Colorectal Dis. 2017;32:1631–7.

25. Hajibandeh S, Hajibandeh S, Matthews J, et al. Meta-analysis of survival and functional outcomes after total mesorectal excision with or without lateral pelvic lymph node dissection in rectal cancer surgery. Surgery. 2020;168(3):486–96.

26. Hiyoshi Y, Miyamoto Y, Kyozumi Y, et al. Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Clin Oncol. 2020;25(1):110–7.

27. Kim JC, Takahashi K, Yu CS, et al. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer. Ann Surg. 2007;246(5):754–62.

28. Sato H, Maeda K, Matuda M. Prognostic significance of lateral lymph node dissection in node positive low rectal carcinoma. Int J Colorectal Dis. 2011;26(7):881–8.

29. Nagasaki T, Akiyoshi T, Fujimoto Y, et al. Preoperative chemoradiotherapy might improve the prognosis of patients with locally advanced low rectal cancer and lateral pelvic lymph node metastases. World J Surg. 2017;41(3):876–83.

30. Yokoyama S, Takifuji K, Hotta T, et al. Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved. Surg Today. 2014;44(6):1097–103.

31. Akiyoshi T, Watanabe T, Miyata S, et al. Results of a Japanese nationwide multi-institutional study on total pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012;255(6):1129–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions